Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 mars 2021 08h00 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting...
09 mars 2021 08h00 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces Upcoming Virtual Investor Conference Participations

Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
08 mars 2021 08h00 HE | Source: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies

Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
01 mars 2021 07h55 HE | Source: Enlivex Therapeutics Ltd

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor...
22 févr. 2021 08h00 HE | Source: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Nes-Ziona, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
18 févr. 2021 08h00 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares

Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
16 févr. 2021 08h30 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy

Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
12 févr. 2021 17h21 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
09 févr. 2021 23h25 HE | Source: Enlivex Therapeutics Ltd

Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
09 févr. 2021 17h25 HE | Source: Enlivex Therapeutics Ltd

Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...

Page précédente